ANon-valvular atrial fibrillation
First line
Non-valvular atrial fibrillation
First line
Edoxaban is a direct oral anticoagulant (DOAC) that inhibits factor Xa; in Spain it is sold as Lixiana. In non-valvular atrial fibrillation it is prescribed to prevent stroke and systemic embolism. Per the AEMPS ficha técnica, the indication covers adults with one or more risk factors such as heart failure, hypertension, age 75 or older, diabetes, or prior stroke or TIA. The 2024 guidelines prefer DOACs over vitamin K antagonists, except in patients with a mechanical valve or moderate to severe mitral stenosis. In ENGAGE AF-TIMI 48 (NEJM 2013, 21,105 patients), edoxaban 60 mg was noninferior to warfarin: stroke or systemic embolism occurred at 1.18 versus 1.50 percent per year, with less major bleeding (2.75 versus 3.43 percent per year) and less intracranial bleeding (0.39 versus 0.85 percent). The usual dose is 60 mg once daily. It drops to 30 mg once daily with at least one of three factors: creatinine clearance 15–50 mL/min, body weight 60 kg or less, or concomitant ciclosporin, dronedarone, erythromycin or ketoconazole. Below 15 mL/min and on dialysis it is not recommended. In ENGAGE AF, efficacy against well-controlled warfarin was lower at higher creatinine clearance. With high clearance the ficha therefore asks for a careful assessment of thrombotic and bleeding risk first, and the label (Savaysa) says not to use edoxaban above 95 mL/min. According to the ficha there is no specific antidote. In Spain the 2016 AEMPS document sets out when the public health system prescribes DOACs, for example when INR control on a vitamin K antagonist is poor.
Sources
- ENGAGE AF-TIMI 48: Edoxaban versus Warfarin in Patients with Atrial Fibrillation (2013)
- ESC: 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). (2024)
- The Lancet: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (2014)
- AEMPS: Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular (IPT UT_ACOD/V5/21112016) (2016)
- AEMPS: Ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (nº registro 115993018) (2025)
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)
ICD-10: I48.9 · ICD-11: BC81.3